A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia published in Nature Biomedical Engineering

January 4, 2020

Congrats to Nisarg, Alex and team on their recent publication which describes a macroporous-biomaterial vaccine for the treatment of acute myeloid lymphoma (AML). The AML vaccine prevented the engraftment of tumor cells when administered as a prophylactic and in combination with chemotherapy, and eradicated established disease even in the absence of defined vaccine antigens. 

Check it out here: A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia